Dyadic International Inc DYAI

FY2025 · ended Dec 31, 2025 · Revenue $3.09M, -11.6% YoY · Filed Mar 25, 2026

Dyadic International Inc (DYAI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.1 million and a net loss of $7.4 million. As of Jun 30, 2026 it held $3.1 million in cash and investments and $5,054 in total debt.

Revenue (TTM)
$3.80M
-8.0% vs year-ago TTM
Net income (TTM)
$-7.62M
-36.7% vs year-ago TTM
Operating cash flow (TTM)
$-7.40M
-148.7% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.21
Dividend per share
None
Shares outstanding
36.44M
+21.1% vs prior year
Net cash
$3.11M
as of Jun 30, 2026
Operating margin
-195.1%
FY 2026

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
DYAI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Jupiter, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1213809
Former names
CCP WORLDWIDE INC (until Nov 5, 2004)

Other Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
$3.1M
$3.5M
$2.9M
$2.9M
$2.4M
Operating income
-$7.2M
-$5.9M
-$8.2M
-$10.2M
-$14.7M
Net income
-$7.4M
-$5.8M
-$6.8M
-$9.7M
-$13.1M
Diluted EPS
-$0.23
—
—
—
—
Operating cash flow
-$5.7M
-$4.0M
-$6.7M
-$8.1M
-$11.3M
Total assets
$9.9M
$9.9M
$8.2M
$13.7M
$21.3M
Total liabilities
$8.7M
$7.5M
$2.3M
$2.6M
$2.9M
Stockholders' equity
$1.2M
$2.5M
$5.9M
$11.1M
$18.4M
Cash and investments
$7.3M
$9.3M
$6.5M
$5.8M
$15.7M
Total debt
$34,621
$88,870
$136,929
—
—

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Listing notice
Sep 25, 2026 Sep 25, 2026
8-K Current report
Material agreement, Unregistered share sale, Other events
Aug 14, 2026 Aug 13, 2026
10-Q Quarterly report Aug 12, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 12, 2026 Aug 12, 2026
8-K Current report
Other events
Jul 24, 2026 Jul 24, 2026
8-K Current report
Shareholder vote results
Jun 22, 2026 Jun 18, 2026

Source: SEC EDGAR filings. This is company-reported data, not investment advice.